The Centers for Disease Control and Prevention (CDC) recently raised alarm bells about serious reactions reported by at least 19 individuals across nine states after receiving botulinum toxin injections in non-healthcare settings or by unlicensed individuals. These reactions ranged from blurry vision to difficulty breathing, symptoms synonymous with botulism.
Among the affected, predominantly females with an average age of 39, 60% required hospitalization, with 21% receiving botulism antitoxin due to concerns of toxin spreading beyond the injection site. Fortunately, botulism tests for five individuals returned negative results.
Collaborating with state and local health departments, as well as the US Food and Drug Administration (FDA), the CDC is delving into these incidents, which spanned Colorado, Florida, Illinois, Kentucky, Nebraska, New Jersey, New York, Tennessee, and Washington. Initial findings suggest some received injections from counterfeit or unverified sources, primarily for cosmetic enhancements.
In light of these events, the American Society for Dermatologic Surgery Association (ASDSA) emphasized the need for heightened oversight, urging states to bolster supervision across medical settings, including spas.
Recognizing the gravity of the situation, the CDC urges clinicians to remain vigilant for botulinum toxin adverse effects, especially near injection sites, advising patients to inquire about providers’ credentials and product authenticity before undergoing injections.
Dr. Lawrence J. Green, a clinical professor of dermatology at George Washington University, expressed deep concern, stressing the necessity of receiving botulinum toxin injections from qualified and licensed professionals in medical settings. He emphasized the variance in standards across practitioners and highlighted the paramount importance of patient safety.
For suspected cases of systemic botulism, the CDC recommends consulting local or state health departments or reaching out to the CDC clinical botulism service directly.